Suppr超能文献

与血液系统恶性肿瘤相关的中性粒细胞性和嗜酸性粒细胞性皮肤病。

Neutrophilic and eosinophilic dermatoses associated with hematological malignancy.

作者信息

Maronese Carlo Alberto, Derlino Federica, Moltrasio Chiara, Cattaneo Daniele, Iurlo Alessandra, Marzano Angelo Valerio

机构信息

Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.

出版信息

Front Med (Lausanne). 2024 Jan 5;10:1324258. doi: 10.3389/fmed.2023.1324258. eCollection 2023.

Abstract

Cutaneous manifestations of hematologic malignancy represent both a clinical challenge for the treating physician and a pathophysiological model for advancing the knowledge on individual neoplasms. Indeed, a growing body of evidence supports the concept of recurrent molecular defects associating with specific clinical features, as best exemplified by VEXAS. Herein neutrophilic and eosinophilic dermatoses of potential interest for both hematologists and dermatologists will be reviewed, including subcorneal pustular dermatosis-type IgA pemphigus, neutrophilic eccrine hidradenitis, Sweet's syndrome as well as myelodysplasia cutis and VEXAS, pyoderma gangrenosum, eosinophilic annular erythema, eosinophilic dermatosis of hematological malignancy, Wells syndrome and cutaneous involvement in hypereosinophilic syndromes. Possible management approaches are discussed for each, emphasizing scenarios that require treatment of the underlying condition to achieve remission at the skin level.

摘要

血液系统恶性肿瘤的皮肤表现对治疗医生来说既是一项临床挑战,也是推进对个体肿瘤认识的病理生理模型。事实上,越来越多的证据支持与特定临床特征相关的复发性分子缺陷这一概念,VEXAS就是最好的例证。本文将综述血液科医生和皮肤科医生可能感兴趣的嗜中性和嗜酸性皮肤病,包括角膜下脓疱性皮肤病型IgA天疱疮、嗜中性小汗腺汗管炎、Sweet综合征以及皮肤骨髓增生异常和VEXAS、坏疽性脓皮病、嗜酸性环状红斑、血液系统恶性肿瘤的嗜酸性皮肤病、Wells综合征和高嗜酸性粒细胞综合征的皮肤受累。针对每种情况讨论了可能的管理方法,重点强调需要治疗基础疾病以实现皮肤层面缓解的情况。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5109/10796805/389834532c8b/fmed-10-1324258-g001.jpg

相似文献

1
Neutrophilic and eosinophilic dermatoses associated with hematological malignancy.
Front Med (Lausanne). 2024 Jan 5;10:1324258. doi: 10.3389/fmed.2023.1324258. eCollection 2023.
2
Neutrophilic dermatoses: a review of current treatment options.
Am J Clin Dermatol. 2009;10(5):301-12. doi: 10.2165/11310730-000000000-00000.
3
Neutrophilic dermatoses.
Rev Med Interne. 2022 Dec;43(12):727-738. doi: 10.1016/j.revmed.2022.06.007. Epub 2022 Jul 20.
4
[Neutrophilic dermatoses].
Rev Med Interne. 2005 Jan;26(1):41-53. doi: 10.1016/j.revmed.2004.06.015.
6
A continuum of neutrophilic disease occurring in a patient with ulcerative colitis.
Australas J Dermatol. 1998 May;39(2):116-8. doi: 10.1111/j.1440-0960.1998.tb01262.x.
10
From acute febrile neutrophilic dermatosis to neutrophilic disease: forty years of clinical research.
J Am Acad Dermatol. 2006 Dec;55(6):1066-71. doi: 10.1016/j.jaad.2006.07.016. Epub 2006 Oct 18.

引用本文的文献

2
Paraneoplastic Dermatoses: A Clue for Underlying Malignancies.
J Clin Med. 2025 Feb 5;14(3):1014. doi: 10.3390/jcm14031014.
3
Intravenous Immunoglobulin Therapy for Pyoderma Gangrenosum: A Multicenter Retrospective Analysis in 81 Patients.
Am J Clin Dermatol. 2025 Jan;26(1):139-146. doi: 10.1007/s40257-024-00904-w. Epub 2024 Nov 14.
4
Clinical features, treatment, and outcome of granulocyte colony stimulating factor-induced sweet syndrome.
Arch Dermatol Res. 2024 Oct 14;316(10):685. doi: 10.1007/s00403-024-03414-1.
6
Exploring the Potential of IL-4 and IL-13 Plasma Levels as Biomarkers in Atopic Dermatitis.
Life (Basel). 2024 Mar 7;14(3):352. doi: 10.3390/life14030352.
7
Comparative immunohistochemical analysis of inflammatory cytokines in distinct subtypes of Sweet syndrome.
Front Immunol. 2024 Mar 11;15:1355681. doi: 10.3389/fimmu.2024.1355681. eCollection 2024.

本文引用的文献

1
Pyoderma Gangrenosum: Treatment Options.
Drugs. 2023 Sep;83(14):1255-1267. doi: 10.1007/s40265-023-01931-3. Epub 2023 Aug 23.
2
Digital Ischemia as a Presenting Feature of Hypereosinophilic Syndrome-Associated Vasculitis.
J Allergy Clin Immunol Pract. 2023 Aug;11(8):2572-2573. doi: 10.1016/j.jaip.2023.05.010. Epub 2023 Jun 26.
4
The international consensus classification of eosinophilic disorders and systemic mastocytosis.
Am J Hematol. 2023 Aug;98(8):1286-1306. doi: 10.1002/ajh.26966. Epub 2023 Jun 7.
7
Hypereosinophilic syndrome with cutaneous manifestations successfully treated with Dupilumab as a sole agent: A case report.
Australas J Dermatol. 2023 Aug;64(3):400-403. doi: 10.1111/ajd.14086. Epub 2023 May 29.
8
How to treat VEXAS syndrome: a systematic review on effectiveness and safety of current treatment strategies.
Rheumatology (Oxford). 2023 Nov 2;62(11):3518-3525. doi: 10.1093/rheumatology/kead240.
9
-Driver and -Passenger Variants in Adult-Onset Autoinflammation.
N Engl J Med. 2023 Apr 27;388(17):1626-1629. doi: 10.1056/NEJMc2212928.
10
Mepolizumab therapy improves the most bothersome symptoms in patients with hypereosinophilic syndrome.
Front Med (Lausanne). 2023 Mar 29;10:1035250. doi: 10.3389/fmed.2023.1035250. eCollection 2023.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验